These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12873147)

  • 1. Investigating the origin of the slow-binding inhibition of HCV NS3 serine protease by a novel substrate based inhibitor.
    Liu Y; Saldivar A; Bess J; Solomon L; Chen CM; Tripathi R; Barrett L; Richardson PL; Molla A; Kohlbrenner W; Kati W
    Biochemistry; 2003 Jul; 42(29):8862-9. PubMed ID: 12873147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.
    Rajagopalan R; Misialek S; Stevens SK; Myszka DG; Brandhuber BJ; Ballard JA; Andrews SW; Seiwert SD; Kossen K
    Biochemistry; 2009 Mar; 48(11):2559-68. PubMed ID: 19209850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.
    Yin Z; Patel SJ; Wang WL; Wang G; Chan WL; Rao KR; Alam J; Jeyaraj DA; Ngew X; Patel V; Beer D; Lim SP; Vasudevan SG; Keller TH
    Bioorg Med Chem Lett; 2006 Jan; 16(1):36-9. PubMed ID: 16246553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
    Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A
    Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
    Yin Z; Patel SJ; Wang WL; Chan WL; Ranga Rao KR; Wang G; Ngew X; Patel V; Beer D; Knox JE; Ma NL; Ehrhardt C; Lim SP; Vasudevan SG; Keller TH
    Bioorg Med Chem Lett; 2006 Jan; 16(1):40-3. PubMed ID: 16246563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism.
    Xu Y; Nakajima Y; Ito K; Zheng H; Oyama H; Heiser U; Hoffmann T; Gärtner UT; Demuth HU; Yoshimoto T
    J Mol Biol; 2008 Jan; 375(3):708-19. PubMed ID: 18042490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease.
    Konstantinidis AK; Richardson PL; Kurtz KA; Tripathi R; Chen CM; Huang P; Randolph J; Towne D; Donnelly J; Warrior U; Middleton T; Kati WM
    Anal Biochem; 2007 Sep; 368(2):156-67. PubMed ID: 17644059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis.
    Sardana VV; Blue JT; Zugay-Murphy J; Sardana MK; Kuo LC
    Protein Expr Purif; 1999 Aug; 16(3):440-7. PubMed ID: 10425166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V
    Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
    Wyss DF; Arasappan A; Senior MM; Wang YS; Beyer BM; Njoroge FG; McCoy MA
    J Med Chem; 2004 May; 47(10):2486-98. PubMed ID: 15115392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors.
    Ismail NS; El Dine RS; Hattori M; Takahashi K; Ihara M
    Bioorg Med Chem; 2008 Sep; 16(17):7877-87. PubMed ID: 18752958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.